Phaseline

Companies › RAPT Therapeutics, Inc., a member of the GSK plc group of companies

RAPT Therapeutics, Inc., a member of the GSK plc group of companies: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RPT904
anti-IgE monoclonal antibody
IGHMPhase 2Immune System DiseasesMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07220811RPT904Phase 2Immune System DiseasesImmunologyMar 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

IGHM (1)

Companies with the same targets

Lycia Therapeutics

Companies built like this

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) AnaptysBio Q32 Bio Chengdu Kangnuoxing Biopharma Ashibio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.